



**MEETING OF THE BORDERS FORMULARY COMMITTEE TO BE HELD
ON WEDNESDAY 14th AUGUST 2019 @ 12:30 P.M. IN THE ESTATES MEETING ROOM**

MINUTE

Present: Alison Wilson (Director of Pharmacy - Chair); Liz Leitch (Formulary Pharmacist); Keith Maclure (Lead Pharmacist); Dr Paul Neary (Cardiology Consultant); Amy Campbell (Rep Junior Doctors); Dr Nicola Henderson (GP); Kate Warner (Minute Secretary)

1. Apologies: Cathryn Park (Lead Clinical Pharmacist)

Item No.	Situation ; Background ;Assessment	Recommendation	Person Responsible	Timescale
2	Welcome and any declarations of interest: - None			
3	BFC meeting held on 12 th June 2019 draft minute was read and approved as an accurate record of the meeting.	Save and upload to Internet	KW	19.08.19
4	Matters Arising From Previous Minute:			
4.1	Cardiology item moved from June BFC meeting to this agenda – Item 7.2			
5	New Medicine Applications & Non Formulary Requests:			
a)	Mepolizumab NMA; Applicant: Emma Dodd; Clinical Director: Dr J Manning; Indication: An add-on treatment for severe refractory eosinophilic asthma in adult patients; Generic Name: Mepolizumab; Brand Name: Nucala; Dosage: 100mg subcut every 4 weeks; Cost: discussed and included in application; Number of patients in first year: 5; Projected increase in patients: potentially yes. LL gave a brief summary of this SMC approved add on therapy given by subcutaneous injection. Two NFR have been approved in past for this. Currently do not have a full respiratory team and advice is sometimes given from NHS Lothian. Respiratory nurses sit with patients for first admission and then reduced time subsequently. Drug trial and side effects outlined; information on ISAs and QALYs in advice and routine weaknesses highlighted by SMC.	Approved for Specialist Use Only Letter to Applicant	KW	20.08.19

b)	Dalbavancin NMA; Applicant: Dr Ed James / Anne Duguid; Indication: On the advice of the Consultant Microbiologist for treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults in patients with known MRSA or as a second line agent to allow patients to access IV therapy where deemed necessary and to prevent admission or reduce hospital length of stay where daily or three times a week therapy is not an option; Generic Name: Dalbavancin Brand Name: Xydalba; Dosage: 1000mg then 500mg after one week; Cost: included in application; Number of patients in first year: 2; Projected increase in patients: Yes. Numbers may increase when in use. LL commented that Dalbavancin has been through a Lothian FAF application. Used for a select group of patients as a once only treatment after which they can return home – rather than once daily in hospital. If approved, more information would be required on administration. There would be no impact on community; with follow up clinic or AAU, monitoring would be through secondary care. LL gave a brief overview of SMC advice and trials undertaken; treatment regimen and comparative treatments. PN asked about resistance as this was not shown in evidence. BFC discussed current options and indications used for once only dose. BFC heard that other Boards follow up with phone call which may be required here. It was agreed that there is a need for definite protocol and formal follow up. To be initiated on advice of consultant microbiologist – this should be included in letter. Ask Ed for protocol and arrangements for out of hours.	BFC agreed that more information was required. Request for protocol and arrangements for follow up. Letter to applicant An out of date NMA form was used; request new form – signatures from EJ and Dr J O'Donnell.	KW	20.08.19
c)	NFR application for Erenumab was discussed; all details in NFR folder and database.	NFR database Letter to applicant	KW	20.08.19
d)	NFR application for Guanfacine was discussed; all details in NFR folder and database.	NFR database Letter to applicant	KW	20.08.19
6	SMC Recommendations			
	June and July 2019 SMC decisions – LL commented on the Buprenorphine subcutaneous application which has been sent to addiction team for consideration. Cystic Fibrosis drugs which have not been approved were discussed. These will come as NFRs and applications coming through Lothian or Borders discussed. LL will request that NHS Lothian PACS2 panel hear any requests and NHS Borders PACS2 panel phones in – as currently happens for Haematology/Oncology PACS2 requests.			
7	Borders Joint Formulary Updates:			
7.1	LL tabled a formulary update for Topical Ibuprofen; there is an increase in prescribing 5% gel and good basis for the benefit. There was a recent increase in price but this fluctuates. BFC approved this update to the formulary; prescribing bulletin update will be required.	BFC Approved Update in Prescribing Bulletin	KMacl	30.08.19
7.2	Cardiology Formulary Review meeting and formulary update was outlined by LL and discussed by BFC. PN will write a short paragraph on anticoagulants and antiplatelets for inclusion in the Prescribing Bulletin. In discussing Nicorandil, the Cardiology group had suggested Scriptswitch message to highlight the association with GI ulceration/bleeding. KMacl commented on	BFC Approved and update to formulary changes highlighted.		

	benchmarking and areas where work has already been done to switch patients; a GP champion is to be recruited to lead on highlighted primary care cardiology prescribing issues from the prescribing data – this has been successful in other boards. Small gains would be through individual patient reviews. Borders are low prescribers of Entresto and this is likely to increase; Tenecteplase cost savings has been identified and approved. PN has actioned this with ambulances but suggested a grand round topic for education on this for wards. LL outlined the proposed cardiology formulary updates. Adding a stronger statement as highlighted for Edoxaban / Apixaban choices.			
7.3	Oral Anticoagulants covered in discussion above.	BFC Approved		
7.4	Disease Modifying Anti-Rheumatic Drugs (DMARDs) - LL outlined choices and changes in formulary update highlighted.	BFC Approved		
7.5	Sinusitis treatment changes highlighted in the formulary.	BFC Approved		
8	Other Items for Approval			
8.1	Melatonin – BFC discussed NHS Lanarkshire letter and pdf from PrescQUIPP which shows costing and analysis. Last year NHS Borders spent just over £247,000 and a switch to Colonis would result in an additional spend of £140,000. The PrescQUIPP article doesn't take into account the Scottish Drug Tariff impact – all Melatonin has been removed from the Tariff which means repeat prescriptions will now need authorisation through our office (which will help us control spend). Estimated 400 patients with prescriptions to be revised and this work will be led by Prescribing Support Team with patient communication agreed with medics first. KMacI commented that Colonis have launched an aggressive marketing campaign and approached wholesalers; the licensed product is more expensive. NHS Borders in agreement with other Boards to approve no change to current use with ADHD children. SMC will be reviewing in September, update to BFC to follow.	BFC Approved maintaining the status quo as per Lanarkshire until the Slenyto [®] products are assessed by SMC, (advice expected in September 2019) and re-visit the situation at that point.		
9.1	Single National Formulary Update. AW updated the group on the attached paper. There is to be a regional approach to implementing the SNF. Project support to be given to implement and roll out including an App. LL commented that is vital to have Borders representation and asked who to contact to ensure Borders clinicians are involved.	BFC Noted Contact for SNF to LL	KW	20.08.19
9	For Information and Noting			
9.1	Melatonin – letter outlining NHS Borders position on Melatonin for jet lag.	BFC Noted		
9.2	Lothian Formulary Committee meeting: 3 rd July 2019 minute for noting.	BFC Noted		
10	A.O.C.B. –			
10.1	Dr A Howell forwarded an application for AOCB but it was agreed that this required more discussion than meeting time and attendees permitted. To be included in September ADTC meeting.	Move to Sept ADTC as not quorate - AH	KW	20.08.19

Next Meeting: **Wednesday 9th October 2019 at 12:30 – Estates Meeting Room**
Items for next meeting: